(Q37278043)

19 August 2017

1 reference

title

The TRAIL apoptotic pathway in cancer onset, progression and therapy (English)

1 reference

19 August 2017

0 references

Ricky W Johnstone

1

0 references

Mark J. Smyth

object named as

Mark J Smyth

series ordinal

3

0 references

author name string

Ailsa J Frew

series ordinal

2

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

19 August 2017

published in

Nature Reviews Cancer

1 reference

19 August 2017

volume

8

1 reference

19 August 2017

issue

10

1 reference

19 August 2017

page(s)

782-798

1 reference

Cell death: critical control points

19 August 2017

cites work

1 reference

31 March 2020

The Hallmarks of Cancer

1 reference

Apoptosis: a link between cancer genetics and chemotherapy

31 March 2020

1 reference

Promoting apoptosis as a strategy for cancer drug discovery

31 March 2020

1 reference

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

31 March 2020

1 reference

Nature's TRAIL--on a path to cancer immunotherapy

31 March 2020

1 reference

TRAIL and its receptors as targets for cancer therapy

31 March 2020

1 reference

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

31 March 2020

1 reference

Identification and characterization of a new member of the TNF family that induces apoptosis

31 March 2020

1 reference

Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

31 March 2020

1 reference

TRAIL signalling: decisions between life and death.

31 March 2020

1 reference

Apoptosis control by death and decoy receptors

31 March 2020

1 reference

Life in the balance: how BH3-only proteins induce apoptosis.

31 March 2020

1 reference

Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis

31 March 2020

1 reference

Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL

31 March 2020

1 reference

Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis

31 March 2020

1 reference

Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression.

31 March 2020

1 reference

Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria

31 March 2020

1 reference

Type I and type II reactions in TRAIL-induced apoptosis -- results from dose-response studies.

31 March 2020

1 reference

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt

31 March 2020

1 reference

Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects

31 March 2020

1 reference

TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB.

31 March 2020

1 reference

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.

31 March 2020

1 reference

Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death.

31 March 2020

1 reference

Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation

31 March 2020

1 reference

Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells.

31 March 2020

1 reference

Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis

31 March 2020

1 reference

CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.

31 March 2020

1 reference

Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease

31 March 2020

1 reference

31 March 2020

1 reference

31 March 2020

1 reference

Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes

31 March 2020

1 reference

Critical roles of TRAIL in hepatic cell death and hepatic inflammation.

31 March 2020

1 reference

TRAIL limits excessive host immune responses in bacterial meningitis

31 March 2020

1 reference

TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis

31 March 2020

1 reference

Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells

31 March 2020

1 reference

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis

31 March 2020

1 reference

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice

31 March 2020

1 reference

Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs

31 March 2020

1 reference

T cells require TRAIL for optimal graft-versus-tumor activity

31 March 2020

1 reference

In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity.

31 March 2020

1 reference

Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor-related apoptosis-inducing ligand: a possible mechanism for poor sensitivity to antitumor immunity

31 March 2020

1 reference

TRAIL-induced cell death cooperates with IFN-γ activation in the graft-versus-tumor effect against colon tumors

31 March 2020

1 reference

On the production of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) by human neutrophils

31 March 2020

1 reference

Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer

31 March 2020

1 reference

Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo.

31 March 2020

1 reference

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

31 March 2020

1 reference

Differential tumor surveillance by natural killer (NK) and NKT cells.

31 March 2020

1 reference

NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.

31 March 2020

1 reference

Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies

31 March 2020

1 reference

Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice

31 March 2020

1 reference

TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development

31 March 2020

1 reference

Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma

31 March 2020

1 reference

Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding

31 March 2020

1 reference

TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies

31 March 2020

1 reference

Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor

31 March 2020

1 reference

Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer

31 March 2020

1 reference

Death receptor 4 variants and colorectal cancer risk.

31 March 2020

1 reference

Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5.

31 March 2020

1 reference

Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women.

31 March 2020

1 reference

TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma

31 March 2020

1 reference

Association of a common variant of the CASP8 gene with reduced risk of breast cancer

31 March 2020

1 reference

Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN

31 March 2020

1 reference

Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines

31 March 2020

1 reference

Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma

31 March 2020

1 reference

Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome

31 March 2020

1 reference

Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients

31 March 2020

1 reference

Safety and antitumor activity of recombinant soluble Apo2 ligand

31 March 2020

1 reference

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

31 March 2020

1 reference

Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4

31 March 2020

1 reference

Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL.

31 March 2020

1 reference

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

31 March 2020

1 reference

Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.

31 March 2020

1 reference

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

31 March 2020

1 reference

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling

31 March 2020

1 reference

Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1.

31 March 2020

1 reference

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy

31 March 2020

1 reference

Fc receptors are required in passive and active immunity to melanoma

31 March 2020

1 reference

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

31 March 2020

1 reference

KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene

31 March 2020

1 reference

Cytotoxicity of TRAIL/anticancer drug combinations in human normal cells

31 March 2020

1 reference

The promise of TRAIL--potential and risks of a novel anticancer therapy

31 March 2020

1 reference

Anticancer activities of histone deacetylase inhibitors

31 March 2020

1 reference

Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells

31 March 2020

1 reference

The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis.

31 March 2020

1 reference

Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma

31 March 2020

1 reference

Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts

31 March 2020

1 reference

Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver

31 March 2020

1 reference

Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist

31 March 2020

1 reference

A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells

31 March 2020

1 reference

Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with speci

31 March 2020

1 reference

Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation

31 March 2020

1 reference

Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance

31 March 2020

1 reference

Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway

31 March 2020

1 reference

mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells

31 March 2020

1 reference

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.

31 March 2020

1 reference

Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy

31 March 2020

1 reference

A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells

31 March 2020

1 reference

A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death

31 March 2020

1 reference

Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein

31 March 2020

1 reference

IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis

31 March 2020

1 reference

IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis

31 March 2020

1 reference

Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis

31 March 2020

1 reference

A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling

31 March 2020

1 reference

Identification of Modulators of TRAIL-Induced Apoptosis via RNAi-Based Phenotypic Screening

31 March 2020

1 reference

A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function

31 March 2020

1 reference

Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway

31 March 2020

1 reference

Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway

31 March 2020

1 reference

Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity.

31 March 2020

1 reference

Cancer immunotherapy: breaking the barriers to harvest the crop

31 March 2020

1 reference

Eradication of established tumors in mice by a combination antibody-based therapy

31 March 2020

1 reference

The immunobiology of cancer immunosurveillance and immunoediting

31 March 2020

1 reference

IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy

31 March 2020

1 reference

Interleukin 21 enhances antibody-mediated tumor rejection

31 March 2020

1 reference

Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition

31 March 2020

1 reference

Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.

31 March 2020

1 reference

Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts

31 March 2020

1 reference

Expression of TRAIL and TRAIL receptors in normal and malignant tissues

31 March 2020

1 reference

Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors

31 March 2020

1 reference

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

31 March 2020

1 reference

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

31 March 2020

1 reference

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

31 March 2020

1 reference

Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents

31 March 2020

1 reference

Who should be sent for genetic testing in hereditary colorectal cancer syndromes?

31 March 2020

1 reference

Assessing individual risk for prostate cancer

31 March 2020

1 reference

Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology

31 March 2020

1 reference

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

31 March 2020

1 reference

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

31 March 2020

1 reference

Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2

31 March 2020

1 reference

Avoiding premature apoptosis of normal epidermal cells

31 March 2020

1 reference

TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse

31 March 2020

1 reference

Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease

31 March 2020

1 reference

NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy

31 March 2020

1 reference

TRAIL-R as a negative regulator of innate immune cell responses.

31 March 2020

1 reference

Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity

31 March 2020

1 reference

Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression

31 March 2020

1 reference

Involvement of TRAIL and its receptors in viral hepatitis

31 March 2020

1 reference

Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake

31 March 2020

1 reference

An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL

31 March 2020

1 reference

Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family

31 March 2020

1 reference

A novel receptor for Apo2L/TRAIL contains a truncated death domain

31 March 2020

1 reference

Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis

31 March 2020

1 reference

Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.

31 March 2020

1 reference

Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway

31 March 2020

1 reference

Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.

31 March 2020

1 reference

Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB

31 March 2020

1 reference

Selective Inhibition of I B Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing Cellular FLIP Level

31 March 2020

1 reference

Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells

31 March 2020

1 reference

Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: role of NF-kappaB inhibition

31 March 2020

1 reference

Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression

31 March 2020

1 reference

Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.

31 March 2020

1 reference

Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells

31 March 2020

1 reference

AKT/PKB signaling: navigating downstream

31 March 2020

1 reference

TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK Pathways

31 March 2020

1 reference

PI-3K/Akt and NF-?B/I?B? pathways are activated in Jurkat T cells in response to TRAIL treatment

31 March 2020

1 reference

Mutant PIK3CA promotes cell growth and invasion of human cancer cells

31 March 2020

1 reference

Differential cleavage of Mst1 by caspase-7/-3 is responsible for TRAIL-induced activation of the MAPK superfamily

31 March 2020

1 reference

Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells

31 March 2020

1 reference

Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase

31 March 2020

1 reference

PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2.

31 March 2020

1 reference

Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway

31 March 2020

1 reference

Inhibition of death receptor signals by cellular FLIP

31 March 2020

1 reference

TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB

31 March 2020

1 reference

Targeting the FLICE Inhibitory Protein (FLIP) in cancer therapy.

31 March 2020

1 reference

Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation.

31 March 2020

1 reference

The inhibitor of apoptosis proteins as therapeutic targets in cancer

31 March 2020

1 reference

IAPs, RINGs and ubiquitylation

31 March 2020

1 reference

Regulation of apoptosis proteins in cancer cells by ubiquitin

31 March 2020

1 reference

Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins

31 March 2020

1 reference

Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition

31 March 2020

1 reference

Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells

31 March 2020

1 reference

Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway

31 March 2020

1 reference

Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.

31 March 2020

1 reference

Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts

31 March 2020

1 reference

Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms

31 March 2020

1 reference

Bid mediates apoptotic synergy between tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and DNA damage.

31 March 2020

1 reference

Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms

31 March 2020

1 reference

Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo

31 March 2020

1 reference

17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway

31 March 2020

1 reference

Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression

31 March 2020

1 reference

Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro

31 March 2020

1 reference

Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL.

31 March 2020

1 reference

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

31 March 2020

1 reference

Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.

31 March 2020

1 reference

Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response

31 March 2020

1 reference

15-Deoxy-delta 12,14-prostaglandin J2 (15d-PGJ 2) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation

31 March 2020

1 reference

Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression

31 March 2020

1 reference

Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer

31 March 2020

1 reference

Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC2465

1 reference

19 August 2017

1 reference